AFFIRM-1
Neuphoria’s Social Anxiety Drug Fails in Phase 3 Trial, Program Discontinued
Neuphoria Therapeutics; BNC210; social anxiety disorder; phase 3 trial; AFFIRM-1; clinical failure; strategic review; PTSD
Actionable Insights Powered by AI
Neuphoria Therapeutics; BNC210; social anxiety disorder; phase 3 trial; AFFIRM-1; clinical failure; strategic review; PTSD